Emerging immune checkpoints for cancer therapy

References

• Wolchok JD, Kluger H, Callahan MK, Postow MA, Rizvi NA, Lesokhin AM, et al. Nivolumab plus ipilimumab in advanced melanoma. N Engl J Med 2013;369:122–33.
   PubMed Web of Science ®Google Scholar
• Yoon SH. Immunotherapy for non-small cell lung cancer. Tuberc Respir Dis (Seoul) 2014;77:111–5.
   PubMedGoogle Scholar
• Bour-Jordan H, Esensten JH, Martinez-Llordella M, Penaranda C, Stumpf M, Bluestone JA. Intrinsic and extrinsic control of peripheral T-cell tolerance by costimulatory molecules of the CD28/ B7 family. Immunol Rev 2011;241:180–205.
   PubMed Web of Science ®Google Scholar
• Pardoll DM. The blockade of immune checkpoints in cancer immunotherapy. Nat Rev Cancer 2012;12: 252–64.
   PubMed Web of Science ®Google Scholar
• Fife BT, Pauken KE, Eagar TN, Obu T, Wu J, Tang Q, et al. Interactions between PD-1 and PD-L1 promote tolerance by blocking the TCR-induced stop signal. Nat Immunol 2009;10:1185–92.
   PubMed Web of Science ®Google Scholar
• Nishimura H, Nose M, Hiai H, Minato N, Honjo T. Development of lupus-like autoimmune diseases by disruption of the PD-1 gene encoding an ITIM motif-carrying immunoreceptor. Immunity 1999;11:141–51.
   PubMed Web of Science ®Google Scholar
• Hodi FS, O’Day SJ, McDermott DF, Weber RW, Sosman JA, Haanen JB, et al. Improved survival with ipilimumab in patients with metastatic melanoma. N Engl J Med 2010; 363:711–23.
   PubMed Web of Science ®Google Scholar
• Ribas A, Kefford R, Marshall MA, Punt CJ, Haanen JB, Marmol M, et al. Phase III randomized clinical trial comparing tremelimumab with standard-of-care chemotherapy in patients with advanced melanoma. J Clin Oncol 2013; 31:616–22.
   PubMed Web of Science ®Google Scholar
• Lynch TJ, Bondarenko I, Luft A, Serwatowski P, Barlesi F, Chacko R, et al. Ipilimumab in combination with paclitaxel and carboplatin as first-line treatment in stage IIIB/IV non-small-cell lung cancer: Results from a randomized, double-blind, multicenter phase II study. J Clin Oncol 2012;30:2046–54.
   PubMed Web of Science ®Google Scholar
• Slovin SF, Higano CS, Hamid O, Tejwani S, Harzstark A, Alumkal JJ, et al. Ipilimumab alone or in combination with radiotherapy in metastatic castration-resistant prostate cancer: Results from an open-label, multicenter phase I/II study. Ann Oncol 2013;24:1813–21.
   PubMed Web of Science ®Google Scholar
• Ansell SM, Hurvitz SA, Koenig PA, LaPlant BR, Kabat BF, Fernando D, et al. Phase I study of ipilimumab, an anti-CTLA-4 monoclonal antibody, in patients with relapsed and refractory B-cell non-Hodgkin lymphoma. Clin Cancer Res 2009;15:6446–53.
   PubMed Web of Science ®Google Scholar
• Topalian SL, Sznol M, McDermott DF, Kluger HM, Carvajal RD, Sharfman WH, et al. Survival, durable tumor remission, and long-term safety in patients with advanced melanoma receiving nivolumab. J Clin Oncol 2014;32: 1020–30.
   PubMed Web of Science ®Google Scholar
• Hamid O, Robert C, Daud A, Hodi FS, Hwu WJ, Kefford R, et al. Safety and tumor responses with lambrolizumab (anti-PD-1) in melanoma. N Engl J Med 2013;369: 134–44.
   PubMed Web of Science ®Google Scholar
• Topalian SL, Hodi FS, Brahmer JR, Gettinger SN, Smith DC, McDermott DF, et al. Safety, activity, and immune correlates of anti-PD-1 antibody in cancer. N Engl J Med 2012;366:2443–54.
   PubMed Web of Science ®Google Scholar
• Brahmer JR, Drake CG, Wollner I, Powderly JD, Picus J, Sharfman WH, et al. Phase I study of single-agent anti-programmed death-1 (MDX-1106) in refractory solid tumors: Safety, clinical activity, pharmacodynamics, and immunologic correlates. J Clin Oncol 2010;28:3167–75.
   PubMed Web of Science ®Google Scholar
• Homet Moreno B, Ribas A. Anti-programmed cell death protein-1/ligand-1 therapy in different cancers. Br J Cancer 2015;112:1421–7.
   PubMed Web of Science ®Google Scholar
• Motzer RJ, Rini BI, McDermott DF, Redman BG, Kuzel TM, Harrison MR, et al. Nivolumab for metastatic renal cell carcinoma: Results of a randomized phase II trial. J Clin Oncol 2015;33:1430–7.
   PubMed Web of Science ®Google Scholar
• Brahmer JR, Tykodi SS, Chow LQ, Hwu WJ, Topalian SL, Hwu P, et al. Safety and activity of anti-PD-L1 antibody in patients with advanced cancer. N Engl J Med 2012;366: 2455–65.
   PubMed Web of Science ®Google Scholar
• Wang-Gillam A, Plambeck-Suess S, Goedegebuure P, Simon PO, Mitchem JB, Hornick JR, et al. A phase I study of IMP321 and gemcitabine as the front-line therapy in patients with advanced pancreatic adenocarcinoma. Invest New Drugs 2013;31:707–13.
   PubMed Web of Science ®Google Scholar
• Ferris RL, Lu B, Kane LP. Too much of a good thing? Tim-3 and TCR signaling in T cell exhaustion. J Immunol 2014;193:1525–30.
   PubMed Web of Science ®Google Scholar
• Ok CY, Chen J, Xu-Monette ZY, Tzankov A, Manyam GC, Li L, et al. Clinical implications of phosphorylated STAT3 expression in De Novo diffuse large B-cell lymphoma. Clin Cancer Res 2014;20:5113–23.
   PubMed Web of Science ®Google Scholar
• Lu L, Xu X, Zhang B, Zhang R, Ji H, Wang X. Combined PD-1 blockade and GITR triggering induce a potent antitumor immunity in murine cancer models and synergizes with chemotherapeutic drugs. J Transl Med 2014; 12:36.
   PubMed Web of Science ®Google Scholar
• Triebel F, Jitsukawa S, Baixeras E, Roman-Roman S, Genevee C, Viegas-Pequignot E, et al. LAG-3, a novel lymphocyte activation gene closely related to CD4. J Exp Med 1990;171:1393–405.
   PubMed Web of Science ®Google Scholar
• Triebel F. LAG-3: A regulator of T-cell and DC responses and its use in therapeutic vaccination. Trends Immunol 2003;24:619–22.
   PubMed Web of Science ®Google Scholar
• Baixeras E, Huard B, Miossec C, Jitsukawa S, Martin M, Hercend T, et al. Characterization of the lymphocyte activation gene 3-encoded protein. A new ligand for human leukocyte antigen class II antigens. J Exp Med 1992;176: 327–37.
   Google Scholar
• Shih K, Arkenau HT, Infante JR. Clinical impact of checkpoint inhibitors as novel cancer therapies. Drugs 2014;74:1993–2013.
   PubMed Web of Science ®Google Scholar
• Workman CJ, Vignali DA. The CD4-related molecule, LAG-3 (CD223), regulates the expansion of activated T cells. Eur J Immunol 2003;33:970–9.
   PubMed Web of Science ®Google Scholar
• Workman CJ, Cauley LS, Kim IJ, Blackman MA, Woodland DL, Vignali DA. Lymphocyte activation gene-3 (CD223) regulates the size of the expanding T cell population following antigen activation in vivo. J Immunol 2004; 172:5450–5.
   PubMed Web of Science ®Google Scholar
• Hannier S, Tournier M, Bismuth G, Triebel F. CD3/TCR complex-associated lymphocyte activation gene-3 molecules inhibit CD3/TCR signaling. J Immunol 1998;161: 4058–65.
   PubMed Web of Science ®Google Scholar
• Hannier S, Triebel F. The MHC class II ligand lymphocyte activation gene-3 is co-distributed with CD8 and CD3-TCR molecules after their engagement by mAb or peptide-MHC class I complexes. Int Immunol 1999;11:1745–52.
   PubMed Web of Science ®Google Scholar
• Gandhi MK, Lambley E, Duraiswamy J, Dua U, Smith C, Elliott S, et al. Expression of LAG-3 by tumor-infiltrating lymphocytes is coincident with the suppression of latent membrane antigen-specific CD8 + T-cell function in Hodgkin lymphoma patients. Blood 2006;108:2280–9.
   PubMed Web of Science ®Google Scholar
• El Mir S, Triebel F. A soluble lymphocyte activation gene-3 molecule used as a vaccine adjuvant elicits greater humoral and cellular immune responses to both particulate and soluble antigens. J Immunol 2000;164:5583–9.
   PubMed Web of Science ®Google Scholar
• Huard B, Tournier M, Hercend T, Triebel F, Faure F. Lymphocyte-activation gene 3/major histocompatibility complex class II interaction modulates the antigenic response of CD4 + T lymphocytes. Eur J Immunol 1994; 24:3216–21.
   PubMed Web of Science ®Google Scholar
• Kisielow M, Kisielow J, Capoferri-Sollami G, Karjalainen K. Expression of lymphocyte activation gene 3 (LAG-3) on B cells is induced by T cells. Eur J Immunol 2005;35: 2081–8.
   PubMed Web of Science ®Google Scholar
• Huard B, Prigent P, Tournier M, Bruniquel D, Triebel F. CD4/major histocompatibility complex class II interaction analyzed with CD4- and lymphocyte activation gene-3 (LAG-3)-Ig fusion proteins. Eur J Immunol 1995;25: 2718–21.
   PubMed Web of Science ®Google Scholar
• Workman CJ, Dugger KJ, Vignali DA. Cutting edge: Molecular analysis of the negative regulatory function of lymphocyte activation gene-3. J Immunol 2002;169:5392–5.
   PubMed Web of Science ®Google Scholar
• Macon-Lemaitre L, Triebel F. The negative regulatory function of the lymphocyte-activation gene-3 co-receptor (CD223) on human T cells. Immunology 2005;115:170–8.
   PubMed Web of Science ®Google Scholar
• Hemon P, Jean-Louis F, Ramgolam K, Brignone C, Viguier M, Bachelez H, et al. MHC class II engagement by its ligand LAG-3 (CD223) contributes to melanoma resistance to apoptosis. J Immunol 2011;186:5173–83.
   PubMed Web of Science ®Google Scholar
• Huang CT, Workman CJ, Flies D, Pan X, Marson AL, Zhou G, et al. Role of LAG-3 in regulatory T cells. Immunity 2004;21:503–13.
   PubMed Web of Science ®Google Scholar
• Liang B, Workman C, Lee J, Chew C, Dale BM, Colonna L, et al. Regulatory T cells inhibit dendritic cells by lymphocyte activation gene-3 engagement of MHC class II. J Immunol 2008;180:5916–26.
   PubMed Web of Science ®Google Scholar
• Durham NM, Nirschl CJ, Jackson CM, Elias J, Kochel CM, Anders RA, et al. Lymphocyte activation gene 3 (LAG-3) modulates the ability of CD4 T-cells to be suppressed in vivo. PLOS One 2014;9:e109080.
   PubMed Web of Science ®Google Scholar
• Okazaki T, Okazaki IM, Wang J, Sugiura D, Nakaki F, Yoshida T, et al. PD-1 and LAG-3 inhibitory co-receptors act synergistically to prevent autoimmunity in mice. J Exp Med 2011;208:395–407.
   PubMed Web of Science ®Google Scholar
• Joosten SA, van Meijgaarden KE, Savage ND, de Boer T, Triebel F, van der Wal A, et al. Identification of a human CD8 + regulatory T cell subset that mediates suppression through the chemokine CC chemokine ligand 4. Proc Natl Acad Sci U S A 2007;104:8029–34.
   PubMed Web of Science ®Google Scholar
• Camisaschi C, Casati C, Rini F, Perego M, De Filippo A, Triebel F, et al. LAG-3 expression defines a subset of CD4(+)CD25(high)Foxp3(+) regulatory T cells that are expanded at tumor sites. J Immunol 2010;184:6545–51.
   PubMed Web of Science ®Google Scholar
• Grosso JF, Goldberg MV, Getnet D, Bruno TC, Yen HR, Pyle KJ, et al. Functionally distinct LAG-3 and PD-1 subsets on activated and chronically stimulated CD8 T cells. J Immunol 2009;182:6659–69.
   PubMed Web of Science ®Google Scholar
• Avice MN, Sarfati M, Triebel F, Delespesse G, Demeure CE. Lymphocyte activation gene-3, a MHC class II ligand expressed on activated T cells, stimulates TNF-alpha and IL-12 production by monocytes and dendritic cells. J Immunol 1999;162:2748–53.
   PubMed Web of Science ®Google Scholar
• Casati C, Camisaschi C, Rini F, Arienti F, Rivoltini L, Triebel F, et al. Soluble human LAG-3 molecule amplifies the in vitro generation of type 1 tumor-specific immunity. Cancer Res 2006;66:4450–60.
   PubMed Web of Science ®Google Scholar
• Byun HJ, Jung WW, Lee DS, Kim S, Kim SJ, Park CG, et al. Proliferation of activated CD1d-restricted NKT cells is down-modulated by lymphocyte activation gene-3 signaling via cell cycle arrest in S phase. Cell Biol Int 2007;31:257–62.
   PubMed Web of Science ®Google Scholar
• Sfanos KS, Bruno TC, Maris CH, Xu L, Thoburn CJ, DeMarzo AM, et al. Phenotypic analysis of prostate- infiltrating lymphocytes reveals TH17 and Treg skewing. Clin Cancer Res 2008;14:3254–61.
   PubMed Web of Science ®Google Scholar
• Li N, Workman CJ, Martin SM, Vignali DA. Biochemical analysis of the regulatory T cell protein lymphocyte activation gene-3 (LAG-3; CD223). J Immunol 2004;173: 6806–12.
   PubMed Web of Science ®Google Scholar
• Andreae S, Buisson S, Triebel F. MHC class II signal transduction in human dendritic cells induced by a natural ligand, the LAG-3 protein (CD223). Blood 2003;102: 2130–7.
   PubMed Web of Science ®Google Scholar
• Workman CJ, Vignali DA. Negative regulation of T cell homeostasis by lymphocyte activation gene-3 (CD223). J Immunol 2005;174:688–95.
   PubMed Web of Science ®Google Scholar
• Llosa NJ, Cruise M, Tam A, Wicks EC, Hechenbleikner EM, Taube JM, et al. The vigorous immune microenvironment of microsatellite instable colon cancer is balanced by multiple counter-inhibitory checkpoints. Cancer Discov 2015; 5:43–51.
   PubMed Web of Science ®Google Scholar
• Gros A, Robbins PF, Yao X, Li YF, Turcotte S, Tran E, et al. PD-1 identifies the patient-specific CD8(+) tumor-reactive repertoire infiltrating human tumors. J Clin Invest 2014; 124:2246–59.
   PubMed Web of Science ®Google Scholar
• Matsuzaki J, Gnjatic S, Mhawech-Fauceglia P, Beck A, Miller A, Tsuji T, et al. Tumor-infiltrating NY-ESO-1- specific CD8 + T cells are negatively regulated by LAG-3 and PD-1 in human ovarian cancer. Proc Natl Acad Sci U S A 2010;107:7875–80.
   PubMed Web of Science ®Google Scholar
• Woo SR, Turnis ME, Goldberg MV, Bankoti J, Selby M, Nirschl CJ, et al. Immune inhibitory molecules LAG-3 and PD-1 synergistically regulate T-cell function to promote tumoral immune escape. Cancer Res 2012;72:917–27.
   PubMed Web of Science ®Google Scholar
• Workman CJ, Wang Y, El Kasmi KC, Pardoll DM, Murray PJ, Drake CG, et al. LAG-3 regulates plasmacytoid dendritic cell homeostasis. J Immunol 2009;182:1885–91.
   PubMed Web of Science ®Google Scholar
• Grosso JF, Kelleher CC, Harris TJ, Maris CH, Hipkiss EL, De Marzo A, et al. LAG-3 regulates CD8 + T cell accumulation and effector function in murine self- and tumor-tolerance systems. J Clin Invest 2007;117:3383–92.
   PubMed Web of Science ®Google Scholar
• Greenwald RJ, Oosterwegel MA, van der Woude D, Kubal A, Mandelbrot DA, Boussiotis VA, et al. CTLA-4 regulates cell cycle progression during a primary immune response. Eur J Immunol 2002;32:366–73.
   PubMed Web of Science ®Google Scholar
• Goding SR, Wilson KA, Xie Y, Harris KM, Baxi A, Akpinarli A, et al. Restoring immune function of tumor-specific CD4 + T cells during recurrence of melanoma. J Immunol 2013;190:4899–909.
   PubMed Web of Science ®Google Scholar
• Fougeray S, Brignone C, Triebel F. A soluble LAG-3 protein as an immunopotentiator for therapeutic vaccines: Preclinical evaluation of IMP321. Vaccine 2006;24:5426–33.
   PubMed Web of Science ®Google Scholar
• Brignone C, Escudier B, Grygar C, Marcu M, Triebel F. A phase I pharmacokinetic and biological correlative study of IMP321, a novel MHC class II agonist, in patients with advanced renal cell carcinoma. Clin Cancer Res 2009; 15:6225–31.
   PubMed Web of Science ®Google Scholar
• Brignone C, Gutierrez M, Mefti F, Brain E, Jarcau R, Cvitkovic F, et al. First-line chemoimmunotherapy in metastatic breast carcinoma: Combination of paclitaxel and IMP321 (LAG-3Ig) enhances immune responses and antitumor activity. J Transl Med 2010;8:71.
   PubMed Web of Science ®Google Scholar
• Anderson AC. Tim-3, a negative regulator of anti-tumor immunity. Curr Opin Immunol 2012;24:213–6.
   PubMed Web of Science ®Google Scholar
• Anderson AC, Anderson DE, Bregoli L, Hastings WD, Kassam N, Lei C, et al. Promotion of tissue inflammation by the immune receptor Tim-3 expressed on innate immune cells. Science 2007;318:1141–3.
   PubMed Web of Science ®Google Scholar
• Ngiow SF, Teng MW, Smyth MJ. Prospects for TIM3-targeted antitumor immunotherapy. Cancer Res 2011;71:6567–71.
   PubMed Web of Science ®Google Scholar
• Wiener Z, Kohalmi B, Pocza P, Jeager J, Tolgyesi G, Toth S, et al. TIM-3 is expressed in melanoma cells and is upregulated in TGF-beta stimulated mast cells. J Invest Dermatol 2007;127:906–14.
   PubMed Web of Science ®Google Scholar
• Zhuang X, Zhang X, Xia X, Zhang C, Liang X, Gao L, et al. Ectopic expression of TIM-3 in lung cancers: A potential independent prognostic factor for patients with NSCLC. Am J Clin Pathol 2012;137:978–85.
   PubMed Web of Science ®Google Scholar
• Yan J, Zhang Y, Zhang JP, Liang J, Li L, Zheng L. Tim-3 expression defines regulatory T cells in human tumors. PLOS One 2013;8:e58006.
   PubMed Web of Science ®Google Scholar
• Cao Y, Zhou X, Huang X, Li Q, Gao L, Jiang L, et al. Tim-3 expression in cervical cancer promotes tumor metastasis. PLOS One 2013;8:e53834.
   PubMed Web of Science ®Google Scholar
• Jiang J, Jin MS, Kong F, Cao D, Ma HX, Jia Z, et al. Decreased galectin-9 and increased Tim-3 expression are related to poor prognosis in gastric cancer. PLOS One 2013;8:e81799.
   PubMed Web of Science ®Google Scholar
• Yang ZZ, Grote DM, Ziesmer SC, Niki T, Hirashima M, Novak AJ, et al. IL-12 upregulates TIM-3 expression and induces T cell exhaustion in patients with follicular B cell non-Hodgkin lymphoma. J Clin Invest 2012;122:1271–82.
   PubMed Web of Science ®Google Scholar
• Sakuishi K, Apetoh L, Sullivan JM, Blazar BR, Kuchroo VK, Anderson AC. Targeting Tim-3 and PD-1 pathways to reverse T cell exhaustion and restore anti-tumor immunity. J Exp Med 2010;207:2187–94.
   PubMed Web of Science ®Google Scholar
• Sakuishi K, Jayaraman P, Behar SM, Anderson AC, Kuchroo VK. Emerging Tim-3 functions in antimicrobial and tumor immunity. Trends Immunol 2011;32:345–9.
   PubMed Web of Science ®Google Scholar
• Monney L, Sabatos CA, Gaglia JL, Ryu A, Waldner H, Chernova T, et al. Th1-specific cell surface protein Tim-3 regulates macrophage activation and severity of an autoimmune disease. Nature 2002;415:536–41.
   PubMed Web of Science ®Google Scholar
• Kozlowska A, Mackiewicz J, Mackiewicz A. Therapeutic gene modified cell based cancer vaccines. Gene 2013;525: 200–7.
   PubMed Web of Science ®Google Scholar
• Sabatos CA, Chakravarti S, Cha E, Schubart A, Sanchez-Fueyo A, Zheng XX, et al. Interaction of Tim-3 and Tim-3 ligand regulates T helper type 1 responses and induction of peripheral tolerance. Nat Immunol 2003;4: 1102–10.
   PubMed Web of Science ®Google Scholar
• Zhu C, Anderson AC, Schubart A, Xiong H, Imitola J, Khoury SJ, et al. The Tim-3 ligand galectin-9 negatively regulates T helper type 1 immunity. Nat Immunol 2005; 6:1245–52.
   PubMed Web of Science ®Google Scholar
• Byrne WL, Mills KH, Lederer JA, O’Sullivan GC. Targeting regulatory T cells in cancer. Cancer Res 2011;71:6915–20.
   PubMed Web of Science ®Google Scholar
• Sakuishi K, Ngiow SF, Sullivan JM, Teng MW, Kuchroo VK, Smyth MJ, et al. TIM3 + FOXP3 + regulatory T cells are tissue-specific promoters of T-cell dysfunction in cancer. Oncoimmunology 2013;2:e23849.
   PubMed Web of Science ®Google Scholar
• Gao X, Zhu Y, Li G, Huang H, Zhang G, Wang F, et al. TIM-3 expression characterizes regulatory T cells in tumor tissues and is associated with lung cancer progression. PLOS One 2012;7:e30676.
   PubMed Web of Science ®Google Scholar
• Woo EY, Yeh H, Chu CS, Schlienger K, Carroll RG, Riley JL, et al. Cutting edge: Regulatory T cells from lung cancer patients directly inhibit autologous T cell proliferation. J Immunol 2002;168:4272–6.
   PubMed Web of Science ®Google Scholar
• Raimondi G, Shufesky WJ, Tokita D, Morelli AE, Thomson AW. Regulated compartmentalization of programmed cell death-1 discriminates CD4 + CD25+ resting regulatory T cells from activated T cells. J Immunol 2006;176:2808–16.
   PubMed Web of Science ®Google Scholar
• Afanasiev OK, Yelistratova L, Miller N, Nagase K, Paulson K, Iyer JG, et al. Merkel polyomavirus-specific T cells fluctuate with merkel cell carcinoma burden and express therapeutically targetable PD-1 and Tim-3 exhaustion markers. Clin Cancer Res 2013;19:5351–60.
   PubMed Web of Science ®Google Scholar
• Nagahara K, Arikawa T, Oomizu S, Kontani K, Nobumoto A, Tateno H, et al. Galectin-9 increases Tim-3 + dendritic cells and CD8 + T cells and enhances antitumor immunity via galectin-9-Tim-3 interactions. J Immunol 2008;181: 7660–9.
   PubMed Web of Science ®Google Scholar
• Simmons WJ, Koneru M, Mohindru M, Thomas R, Cutro S, Singh P, et al. Tim-3 + T-bet+ tumor-specific Th1 cells colocalize with and inhibit development and growth of murine neoplasms. J Immunol 2005;174:1405–15.
   PubMed Web of Science ®Google Scholar
• Hafler DA, Kuchroo V. TIMs: Central regulators of immune responses. J Exp Med 2008;205:2699–701.
   PubMed Web of Science ®Google Scholar
• Takamura S, Tsuji-Kawahara S, Yagita H, Akiba H, Sakamoto M, Chikaishi T, et al. Premature terminal exhaustion of Friend virus-specific effector CD8 + T cells by rapid induction of multiple inhibitory receptors. J Immunol 2010;184:4696–707.
   PubMed Web of Science ®Google Scholar
• Gupta S, Thornley TB, Gao W, Larocca R, Turka LA, Kuchroo VK, et al. Allograft rejection is restrained by short-lived TIM-3 + PD-1 + Foxp3 + Tregs. J Clin Invest 2012;122:2395–404.
   PubMed Web of Science ®Google Scholar
• Wherry EJ. T cell exhaustion. Nat Immunol 2011; 12:492–9.
   PubMed Web of Science ®Google Scholar
• Barber DL, Wherry EJ, Masopust D, Zhu B, Allison JP, Sharpe AH, et al. Restoring function in exhausted CD8 T cells during chronic viral infection. Nature 2006;439: 682–7.
   PubMed Web of Science ®Google Scholar
• Zhou Q, Munger ME, Veenstra RG, Weigel BJ, Hirashima M, Munn DH, et al. Coexpression of Tim-3 and PD-1 identifies a CD8 + T-cell exhaustion phenotype in mice with disseminated acute myelogenous leukemia. Blood 2011;117: 4501–10.
   PubMed Web of Science ®Google Scholar
• Fourcade J, Sun Z, Pagliano O, Guillaume P, Luescher IF, Sander C, et al. CD8(+) T cells specific for tumor antigens can be rendered dysfunctional by the tumor microenvironment through upregulation of the inhibitory receptors BTLA and PD-1. Cancer Res 2012;72:887–96.
   PubMed Web of Science ®Google Scholar
• Fourcade J, Sun Z, Benallaoua M, Guillaume P, Luescher IF, Sander C, et al. Upregulation of Tim-3 and PD-1 expression is associated with tumor antigen-specific CD8 + T cell dysfunction in melanoma patients. J Exp Med 2010; 207:2175–86.
   PubMed Web of Science ®Google Scholar
• Wu J, Liu C, Qian S, Hou H. The expression of Tim-3 in peripheral blood of ovarian cancer. DNA Cell Biol 2013;32:648–53.
   PubMed Web of Science ®Google Scholar
• Fang L, Lowther DE, Meizlish ML, Anderson RC, Bruce JN, Devine L, et al. The immune cell infiltrate populating meningiomas is composed of mature, antigen-experienced T and B cells. Neuro Oncol 2013;15:1479–90.
   PubMed Web of Science ®Google Scholar
• Tong D, Zhou Y, Chen W, Deng Y, Li L, Jia Z, et al. T cell immunoglobulin- and mucin-domain-containing molecule 3 gene polymorphisms and susceptibility to pancreatic cancer. Mol Biol Rep 2012;39:9941–6.
   PubMed Web of Science ®Google Scholar
• Han S, Feng S, Xu L, Shi W, Wang X, Wang H, et al. Tim-3 on peripheral CD4(+) and CD8(+) T cells is involved in the development of glioma. DNA Cell Biol 2014;33:245–50.
   PubMed Web of Science ®Google Scholar
• Piao YR, Jin ZH, Yuan KC, Jin XS. Analysis of Tim-3 as a therapeutic target in prostate cancer. Tumour Biol 2014; 35:11409–14.
   PubMed Web of Science ®Google Scholar
• Postow MA. Managing immune checkpoint-blocking antibody side effects. Am Soc Clin Oncol Educ Book 2015; 35:76–83.
   Google Scholar